Ceapro Inc V.CZO

AVN trial delays

[Ciao]

Why recruiting for the AVN trial did not begin in early 2023 is puzzling. The reason was that the Ethics Committee had to approve the study which IMHO sounds routine. AVN has a well known safety profile. I'm sure the BG pill study had to go through the Ethics Committee especially given that some patients wanted BG as a stand alone therapy. Whatever the process is, it should have been accounted for when the statement was made that recruiting for the study would begin in early 2023.

Given Ronnie's prior history with MHI when he was in Roche, where is his influence if needed to expedite a routine review?

https://www.icm-mhi.org/en/montreal-heart-institute-becomes-roche-global-research-hub-cardiometabolic-disease

[prophetoffactz]

"Why recruiting for the AVN trial did not begin in early 2023 is puzzling. The reason was that the Ethics Committee had to approve the study which IMHO sounds routine. AVN has a well known safety profile." The Montreal Heart Institute assumes responsibility for the clinical trial as Gilles noted. Its Ethics Committe needed all questions addressed to minimize risks to patients. Up to

[Ciao]

The purpose of the phase 1 study is the evaluation for safety, side effects and dosage; here's the function of the Ethics Committee which screens out studies to ensure some protection to subjects who partake in the clinical studies. Obviously patients will be monitored closely during the study for adverse effects, the Ethics Committee will just ensure that at a minimum best clinical practices

[prophetoffactz]

That a three day stay in the hospital is required is a significant statement. This isn't take it and go home. What is the highest dose of avenanthramide that has ever been administered and what were the side-effects? Trialist is a synthetic analog of avenanthramide. How high have they taken the dose of Trialist and what were the side effects? CZO may have had to hunt down as much prevous

[Hopeforthebest]

I have always said that gagnon maybe a good scientist but is a failure as a businessman as evident by the condition of Czo in the investment community and the many questionable actions in running day to day operations. Now with this coming light he is showing that he is also a failure as a scientist. They always talk about the pipeline that is where the value lies, well when you have a

[Ciao]

Looks like a double whammy here.  Base business is taking some lumps now and the trials (AVN delayed start, Y-BG questionable Go decision) and coupled with the PGX scale up which was moved back about 6 months to mid-2024 target vs end of 2023) has the share price at a 52 week low after the company announced it's best yearly financial performance to date We do have a target of a CoQ10

[Stinzo]

Sorry to say Ciao, but with no insider buying in years, I do not think we will see any reversal in that trend any time soon.  To me it looks like a wait and see until Q3 results are out in November, as its pretty clear Q2 will also disapoint and most likely there will be limited announcement on the rest as I expect little activity in July/August in current market conditions with the past

[Ciao]

Stinzo, if in the know insiders have confidence in Gilles leadership and his narrative for the transition or transformation of the company then this is an opportune time for them to step in with purchases in the open market. Otherwise the current share price is a true condemnation of management. If insiders are not buying then it'll be much harder for retail investors to believe in the

[Hopeforthebest]

Ciao, these last 2 weeks have really been concerning with the development of trial delays PGX scale up delayetc. This must of been known at the time of the AGM. Why wasn't his brought to light to the investor, shareholder (who are the true owners of the comapny). this borders lying and if so gagnon and he band of maurders should be held accountable. At this same time, proh involvement within

[Ciao]

Trial delays were commented at the AGM. The 6 month push out of the PGX scale up completion has yet to be explained and the date was pushed out months after the date was set.

[Alex1726]

Gagnon showed us a little computer drawing telling us he could not show more , well that's because he has nothing to show. I have already mentionned that he decided to delay all new development because he knows he does not have the cash to move them all forward , so he will have to make a choice and  making a choice means managing and Gagnon does not have the skills to manage. If he does

[Alex1726]

By the way that's the reason he decided to become Robin Hood Gagnon with the AV floor. He might knows that orders from symrise will never regain the level of the past years.

[prophetoffactz]

"I have already mentionned that he decided to delay all new development because he knows he does not have the cash to move them all forward" The facility for PGX scale-up has been budgeted already. It's only about $5-$6 million and CZO has over $12 million cash plus cashlow. CZO has more than enough cash. The site license with the University of Alberta has been signed. The equipment

[prophetoffactz]

The 6 month push out of the PGX scale up completion has yet to be explained and the date was pushed out months after the date was set. In the August 4, 2022 Small Cap Discoveries interview at 12:15 Gilles expected to be on the market in 12-18 months he said. Ceapro (TSX.V: CZO) Interview with CEO Gilles Gagnon - YouTube That was before CZO had even signed the site agreement with the